The filing is routine and small in scale. Monitor for any subsequent large insider sales or changes in Flagship's ownership, but no immediate trading action warranted.
MRNA drugs
MRNA drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 21 $47.19entry
- T+1 · 6mo ago −0.63%α −1.08% · $46.89
- T+5 · 6mo ago −0.30%α −2.15% · $47.05
- T+20 · 5mo ago +35.53%α +34.99% · $63.96
- T+60 · 3mo ago +36.59%α +32.56% · $64.46
Price Chart
How similar events traded
Executive Summary
Flagship Pioneering, LLC, a major early investor in Moderna, filed a Form 144 to sell 9,263 shares of common stock with an aggregate market value of $433,880. The sale is tied to a cashless exercise of options expiring August 10, 2026. The relatively small share count (0.05% of market cap) suggests routine portfolio management rather than a negative signal.
Key Facts
- Selling entity: Flagship Pioneering, LLC (early-stage venture capital investor and affiliate).
- Proposed sale: 9,263 shares of Moderna common stock.
- Aggregate market value: $433,879.85.
- Shares sourced from cashless exercise of options granted on 08/10/2016, set to expire 08/10/2026.
- Sale represents approximately 0.05% of Moderna's $19.1B market cap.
Financial Impact
Sale of $434k worth of stock, immaterial relative to $19.1B market cap.
Risk Factors
- Insider selling could signal reduced conviction if it becomes a pattern.
- Option expiration may prompt additional sales before August 2026.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001959173-26-003865 |
| Document: 0001959173-26-003865-index.html | 0001959173-26-003865 |
| Document: 0001959173-26-003865.txt | 0001959173-26-003865 |
Track record
26 reports on MRNA
6 of 8 bullish or bearish reports moved the stock their way by T+1. Best: +14.15% at T+60 after the Mar 5, 2026 report. 7 of 8 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 3/10 Entry $217.29 Now $215.27 −0.93% settles Nov 17
- Nov 13, 20263d ago 8-K Neutral 3/10 Entry $222.50 Now $215.27 −3.25% settles Nov 17
- Nov 6, 202610d ago 8-K Bullish 7/10 Entry $254.19 to $269.00 Now $215.27 −15.31% ▲ +5.83% +3.46% vs SPY
- Nov 5, 202611d ago SC 13G/A Neutral 3/10 Entry $241.46 to $254.19 Now $215.27 −10.85% ▲ +5.27% +4.96% vs SPY
- Oct 28, 202619d ago Institutional Cluster Neutral 3/10 Entry $214.17 to $222.76 Now $215.27 +0.52% ▲ +4.01% +4.40% vs SPY
- Oct 27, 202620d ago ANALYST-DOWNGRADE Bearish 4/10 Entry $207.97 to $214.17 Now $215.27 −3.51% ▼ −2.98% −2.63% vs SPY
- Sep 30, 20266w ago 8-K Neutral 3/10 Entry $192.57 to $188.94 Now $215.27 +11.79% ▼ −1.89% −2.06% vs SPY
- Sep 30, 20266w ago ANALYST-DOWNGRADE Bearish 4/10 No price data
- Sep 16, 20268w ago Insider Cluster Bearish 5/10 Entry $158.07 to $154.04 Now $215.27 −36.19% ▲ +2.55% +2.43% vs SPY
- Sep 3, 202610w ago ANALYST-DOWNGRADE Bearish 6/10 Entry $148.87 to $145.55 Now $215.27 −44.60% ▲ +2.23% +1.84% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers